By Lily Caruso · Tuesday, September 8, 2026 · Three days of news, read in thirty minutes. What I watched this morning was the order the market read them in, because the order is the story. It read oil first.
At 6:44, on TheStreet's stamp, Brent was $98.51 and WTI $93.81 — $4.70 apart, which is the spread you'd expect, and the check this desk now runs on every oil number before it prints. Then it read the Fed, because a barrel near $98 is Friday's CPI print wearing a different hat: the 10-year Treasury yield went above 4.8 percent this morning, which Trading Economics and FX.co both call the highest since October 2023, with the 2-year at 4.39, the 30-year at 5.24, and the CME's odds of a hike next Wednesday at about 58 percent on both counts — right where Friday left them. Only then did it read the war.
And here is the tell. Gold fell $31, to $4,445.60, in the same summary that had crude up $1.72. On a morning of Houthi missiles into Saudi Arabia and American strikes on Iranian tankers, the safe haven went down.
When that happens, the market is telling you which fear is in charge, and it isn't the missiles. It's the Fed. That's the ranking this desk has written about since August, and it got confirmed again this morning by the two commodities that can't pretend otherwise.
The open, on Yahoo Finance's first summary after the bell and on Trading Economics' later stamp — two verdicts on the same half hour, both of them stamps, neither a settlement: Index Yahoo opening stamp Trading Economics, mid-morning S&P 500 7,690.84, −0.36% 7,707.60, −0.14% Dow 52,908.91, −0.95% 52,999.87, −0.78% Nasdaq Composite 26,410.44, −0.36% — Nasdaq-100 — 29,544.16, +0.21% Russell 2000 2,962.51, −0.44% — VIX 15.70, +2.6% — A Dow down five hundred on oil and rates, and a Nasdaq-100 that had already turned green on Intel and Oracle by the time the second stamp landed. That's the first verdict being written while I type. The second one comes at four, and the rest of this brief is about which of those two tapes gets to keep it.
THE FIRST ROOM: OIL GREW A SECOND FRONT. The weekend, in order, per NPR and Al Jazeera. On Saturday the Revolutionary Guard fired two ballistic missiles at an American carrier and a destroyer in the Gulf.
Both ships evaded them; no one was hurt. Within hours CENTCOM hit three Iranian tankers — one off Kharg Island, one near Jask, and one in the Gulf of Oman that was struck in what the Navy called multiple critical locations, after which its crew abandoned ship. I keep thinking about that crew, because a tanker war is fought by people who aren't at war with anyone.
Admiral Brad Cooper put the ledger on the record: "If you shoot at two of our ships, we will impose an even higher economic cost — taking out three of yours." Defense Secretary Hegseth was blunter: if Iran shoots at U.S. ships, "we will destroy (and sink) their oil tankers." Tehran called the strikes a war crime, said its navy had targeted three tankers using an "unauthorised route" and three U.S.-linked vessels elsewhere, repeated its threat of a new "restricted zone" beyond the strait — the one Episode 33 said hadn't been drawn yet; one market note describes it as already declared on state media, but I haven't seen a boundary, so here it stays a threat — and on Sunday, per the AP by way of Al Jazeera, claimed to have hit an unmanned American vessel trying to enter the strait. Then, overnight, the second front. Houthi forces fired dozens of missiles and drones into southern Saudi Arabia — at Aramco facilities in Abha and Jazan, and at air bases in Najran and Khamis Mushait — and their spokesman, Yahya Saree, claimed it in a prerecorded video.
Seoul Economic Daily reports the stated reason as retaliation for 121 coalition airstrikes on Yemeni cities. The Saudi count is 73 civilians wounded. The energy ministry suspended operations at several oil facilities and utilities while firefighters put the fires out, per Quartz.
The coalition spokesman, Major General Turki al-Malki, called it "a serious escalation" and, in Seoul Economic Daily's account, "a clear violation of Saudi sovereignty and a direct threat to the safety and security of Saudi citizens and residents." A deputy defense minister said Riyadh intends to retake Sanaa. The Houthis threatened the Bab el-Mandeb. Hold the two maps side by side.
At the top of the Gulf, a strait where Kpler counted five, eleven and six transits on three days last week, against a ten-day average of thirteen and a pre-war baseline of about 130. At the bottom of the Red Sea, a strait the Houthis are threatening to close. Oil doesn't need either one to shut.
It needs both to be uncertain at the same time, and this morning they are. Trade Nation's David Morrison said the obvious thing well: "This appears to be a major escalation and tensions have once again ratcheted higher." The prices, in pairs, always. Seoul Economic Daily: November Brent $98.45, up 1.45 percent, beside October WTI $93.91, up 2.6.
Quartz: WTI $93.84, Brent approaching $100. Trading Economics: WTI around $94, its highest since June 3; Brent near $99; the month running plus 11.5 percent for Brent and plus 12.8 for WTI. The Strategic Petroleum Reserve is under 290 million barrels, the lowest since 1982, which is why the American side of this has less cushion than the headline suggests.
The relief valve, if there is one, is the Iran–Oman route — seven miles wide, through Iranian waters, by Iranian permission — which Tehran says "could soon" open as a temporary passage. And one sentence I read twice. Ali Akbar Dareini of the Tehran Center for Strategic Studies told Al Jazeera that Iran has "plans to make sure that oil prices will shoot up over $100 per barrel." Plan or hope, the tape is two dollars from finding out.
THE SECOND ROOM: NOVARTIS, THREE TIMES IN ONE WEEK. Companies don't usually have weeks like this. On Friday, September 4 — the date on both companies' releases — Novartis and its partner Ionis said that pelacarsen, the drug that was supposed to prove the lipoprotein(a) hypothesis, had failed its 8,323-patient outcomes trial.
It lowered Lp(a) by about 72 percent, per Fierce Biotech's reading of the data, and it did not reduce heart attacks, strokes or cardiovascular death. Novartis's chief medical officer, Shreeram Aradhye, wrote the sentence carefully: "Although lower Lp(a) levels were observed with pelacarsen, the findings did not demonstrate that this translated into reduced cardiovascular risk." Ionis's Brett Monia used the word "disappointed." Then this morning, the second: del-desiran — the centerpiece of the $12 billion Avidity acquisition, a drug the CEO told Bloomberg TV in July had "$5 billion-plus peak sales potential" — failed its Phase 3 in myotonic dystrophy. The endpoint was how fast a patient's hand opens after a squeeze, measured on video.
The hands didn't open faster than they did on placebo. And the same week, per Business Standard, an experimental cell therapy for autoimmune disease was halted after three patients died. Zurich's verdict, at 7:05 GMT on Reuters' stamp, was 8.8 percent down; Business Standard had it as much as 10 percent lower in early trade; CNBC's headline says the stock is heading for its worst day on record.
Vontobel's Stefan Schneider called it a "major pipeline setback" that "has not helped our confidence" in the rest of what Novartis bought from Avidity. Jefferies' Michael Leuchten said the questions about growth after 2030 will come back now. Here is the American part, and the reason it's in a Tuesday brief.
Our market was closed on Monday, so the pelacarsen read-through is getting its first verdict today, four days late. Ionis was down 10.5 percent before the open on TheStreet's count. Amgen, which has its own Lp(a) drug in the 90-percent-lowering class, was off 5 to 6 percent on the morning's stamps after BMO cut it to Market Perform with a $450 target.
Lilly, with lepodisiran, is under pressure. Dyne, the myotonic-dystrophy rival that rallied when Novartis bought Avidity last year, is down 30 percent on del-desiran's failure; Sarepta 11; NewAmsterdam, a cholesterol name that wasn't in either trial, 9 — because the crowd sells the category before it reads the labels. Two analysts drew the line the honest way.
William Blair: deeper Lp(a) inhibition may be necessary, but there is "meaningful risk to a potential future in Lp(a)-driven CVD trials." Citi: they would "not declare the mechanism dead," because if the benefit requires crossing a biological threshold, a 90-percent drug may cross it where a 72-percent drug didn't. I wrote in the KRAS investigation that the market pays for a mechanism long before it pays for an outcome, and that those are two different bets. This is that sentence with a price attached.
A biomarker fell by three-quarters and the people didn't get better. The class isn't dead. The free ride is.
THE THIRD ROOM: MEMORY MET A CURRENCY. Seoul first. The Kospi opened at 7,045.79 — above 7,000 in a session for the first time since August 18, fifteen sessions ago — ran as high as 7,171.52, and closed at 6,954.52, down 0.58 percent: a 217-point round trip from the high to the bell, per Seoul Economic Daily.
The Kosdaq lost 1.25. Samsung finished at 269,500 won, down 0.19 percent; SK hynix at 1.793 million, up 0.56. The story underneath is who was on each side: foreigners bought a net 3.7 trillion won between September 3 and today, and Korean retail investors sold 14.5 trillion.
Households handing the memory trade to institutions at 7,000 is either the smartest thing on the tape or the saddest, and I don't know which yet. Meritz's Lee Jin-woo said what this desk keeps saying about the whole AI complex — that it is "inevitably sensitive to rates given that Big Tech is funding its spending through debt." Goldman's Timothy Moe is still holding a 12,000 target on the argument that "the market is underestimating how long the current earnings cycle will last." Both can be right. Only one of them is right this week.
Tokyo second, and this is the room to study. The Nikkei fell 1,130.51 points, 1.70 percent, to 65,269 — Business Standard and News On Japan agree on the close — and the Topix lost 1.83. Not chips, not oil: the yen, which surged to about 153 to the dollar, its strongest since February 18, after July wages printed the fastest growth since 1997 and second-quarter GDP was revised up to 1.4 percent annualized from 1.1.
A stronger yen is a weaker exporter the day it happens and a faster Bank of Japan the day after, and the carry trade unwound on both. The casualties were the names the memory trade had been carrying: Taiyo Yuden down 7.9 percent, Ibiden 6.3, Kioxia 3.6, Advantest 2. Memory survived the rates fear all summer.
It hadn't yet been tested by a currency. Tokyo just ran the test. Then the American side, where the same trade looks fine at the open.
Foxconn's August revenue, which I said on Sunday would be the first read on whether the Dell and HPE order books were reaching the factories, reached them: NT$921.8 billion, about $29.15 billion, up 52 percent from a year earlier and the second straight month above NT$900 billion, with the company saying third-quarter "operations are expected to gradually gain momentum" as AI demand grows and the consumer season starts. Intel is among the morning's S&P leaders, up 5.5 percent on Yahoo's stamp from Friday's $95.80, after Northland upgraded it to Outperform with a $120 target, citing "turnaround progress, server CPU shortages, and the Terafab partnership" — yes, that Terafab, the Tesla chip plant from last week's investigation — alongside an Intel–ASML disclosure that its foundry has run more than a million wafers on High-NA EUV, and a DigiTimes report that PC processor prices go up about 10 percent in early October. Micron is up half a percent, holding above $1,000, the line in my colleague's Friday row.
SanDisk is up 2.2. Nvidia is fractionally red. Oracle is up 3.7 percent ahead of Thursday's report, and ASML 2 on the High-NA commitments from Samsung, TSMC and Intel.
A correction, at full size. Episode 33 printed Samsung up 5.28 percent and SK hynix up 7.77 percent for Monday's session. Those were Trading Economics stamps taken during the session.
The closes, per Seoul Economic Daily, were plus 5.68 and plus 8.26 — and today's figures above are consistent with them to the won. The Kospi's 6,995.39 close stands; two sources agree on it. THE FOURTH ROOM: TWO TRADE STORIES ON ONE MORNING.
China's customs data landed overnight: exports up 25 percent from a year earlier, faster than July's 23.9; imports up 28.2; a surplus of $119.1 billion, up from $112.5 billion. Autos, industrial machinery and semiconductors led. BNP Paribas Asset Management's Chi Lo: "China has moved aggressively up the value chain and has become a major player in AI infrastructure." Beijing also put about $54 billion into state banks and insurers on Sunday, which is what a government does when the export machine is running and the domestic one isn't.
Tonight brings China's August CPI and PPI; late this month, a Trump–Xi meeting. And this morning, at the northern border, the counter-tariffs Ottawa announced on August 25 took effect: 15, 25 and 50 percent, "dollar for dollar, rate for rate" against the 50 percent U.S. tariffs, on nearly $20 billion a year of American steel, dairy, appliances, farm equipment, pulp and paper and electronics, with C$7.5 billion set aside for the Canadian workers and businesses on the wrong end of them. Mark Carney's sentence from August is still the frame: "You're at war when you get attacked.
We got attacked." Read the two stories together. The largest exporter on earth is accelerating, and the closest trading partner America has is retaliating, on the same morning, with a CPI print three days away. That's the inflation picture Capital.com's Kyle Rodda called "murkier" this morning, and murk gets priced in the 10-year before it gets priced anywhere else.
THE FIFTH ROOM: APPLE, TOMORROW, WITH A ROW ON THE LINE. Apple's "Surprise and shine" event is Wednesday. The estimates that matter are TrendForce's, as reported by MacRumors: iPhone 18 Pro at $1,249 to $1,299 against the 17 Pro's $1,099, the Pro Max at $1,349 to $1,399, and the foldable "Ultra" at $2,099 to $2,299 — because, per the same firm, the cost of a 256-gigabyte memory chip is up nearly 400 percent in a year and the bill of materials on a 256-gigabyte Pro is up about 38 percent.
That's the memory shortage arriving in your pocket, and it's why Sunday's row exists: 60% that the iPhone 18 Pro's announced U.S. starting price is at or above $1,199. It grades tomorrow, on Apple's own newsroom page. Apple closed Friday at $319.88, down 2.54 percent.
THE REST OF THE DAY, AND THE WEEK. The Treasury sells 3-year notes at 1:00 — the first of three auctions, with the 10-year Wednesday and the 30-year Thursday, into a bond market that just printed a 2023 number. The NFIB's small-business optimism index slipped to 98.7 in August from 99.8, below forecasts.
GameStop and Casey's report after the close. Roivant is the day's biggest gainer, up 18.7 to 20 percent on the early stamps, after its Pulmovant unit's mosliciguat cut pulmonary vascular resistance by 56.3 percent against placebo in a Phase 2 study of pulmonary hypertension in lung disease; the Phase 3 is already running. Pivotal Research started SpaceX at Buy with a $220 target, with SPCX at $148.88 premarket.
UBS upgraded Lockheed to Buy at $674. Zim is up 6 on a revised takeover approach. And the index changes from Sunday's brief are trading: Bloom Energy up 5.9 percent, Everpure 3, Illumina 0.9 on the early stamps, ahead of their September 21 entry into the S&P 500.
Wednesday: Apple, the 10-year auction, and Episode 28's XLF-versus-XLU row grades at the close. Thursday: the ECB at 8:15 AM Eastern, where Episode 33 has 55 percent on a hike; PPI; the 30-year; Oracle and Adobe after the bell. Friday: CPI and real earnings at 8:30, and the settlement day for most of the book — Episode 33's 75% real earnings down year over year and 60% Brent settles above $95; my 60% Russell trails the S&P, 55% FedWatch above 60% and 65% WTI above $90; my colleague's Micron above $1,000 and Tesla below $376.37.
Tesla closed Friday at $354.08. The Fed is in its blackout; nobody official speaks until the decision on Wednesday the 16th. One line of house news.
Registration for the TrendyVest Trading Competition opened this morning; my colleague's column on who we are and how the Tournament works ran at the open, and the leaderboard goes live October 1. THE ROWS. Row one — 55% that November Brent settles at or above $100 on at least one day between today and Friday, September 11.
Two dollars away, two fronts open, and a stated Iranian intention to get it there. Falsifier: the Oman corridor opens and transits recover toward the ten-day average, or Riyadh and the Houthis stop. Settlement: the ICE Brent front-month settlement as reported by Reuters and confirmed on a second feed.
A stamp doesn't count. Row two — 55% that the 10-year's H.15 close on Friday, September 11 is at or above 4.80%. It touched the number this morning; the question is whether Friday's CPI lets it keep it.
Falsifier: a core print soft enough to pull the hike odds under 50. Settlement: the Federal Reserve's H.15 daily table, named here as the rule requires. Row three — 60% that the Kospi closes above 7,000 at least once by Friday, September 11.
It's 46 points away, the foreign bid is 3.7 trillion won deep, and today's fade was rates, not earnings. Falsifier: the yen's move finds the won, or CPI takes the memory trade down with the rest of the AI tape. Settlement: the Korea Exchange's official close, per Seoul Economic Daily and one other source.
Row four — 55% that Intel closes Friday, September 11 above $100. It's there this morning on an upgrade and a price hike; a week is long enough for the tape to decide whether a server-CPU shortage is a story or a margin. Falsifier: the chip tape reverses on rates.
Settlement: the Nasdaq official close, two sources. Grading notes. Nothing on the book settles today.
Sunday's iPhone row grades Wednesday. Episode 28's XLF-versus-XLU grades Wednesday at the close. The rest is Friday, on the settlement sources named in each row. — Lily Caruso This is TrendyVest's analysis and opinion — for informational purposes only, not investment advice or a recommendation to buy or sell any security or commodity.
Do your own research.